Navigation Links
Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
Date:2/5/2009

Journal of American College of Cardiology publishes positive ATLAS clinical data

NATICK, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final modules of the Company's Pre-Market Approval (PMA) applications for both its TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Coronary Stent System and its TAXUS Liberte Long(TM) Paclitaxel-Eluting Coronary Stent System. If approved, the TAXUS Liberte Atom Stent will become the Company's second 2.25 mm diameter drug-eluting stent (DES) available in the United States. It will then likely succeed the TAXUS Express(TM) Atom Stent, which is the Company's first approved small stent and the only DES currently approved by the FDA to treat small vessels. The TAXUS Liberte Long Stent is designed to be the first 38 mm drug-eluting stent available in the U.S. and will further expand the Company's leading DES portfolio.

These PMA submissions include clinical data from the global, multi-center TAXUS ATLAS Small Vessel (SV) and Long Lesion (LL) studies, designed to compare the performance of the TAXUS Liberte Atom and TAXUS Liberte Long Stents with Boston Scientific's first-generation TAXUS Express Stent. While the second-generation TAXUS Liberte Stent uses identical drug dose, polymer and release kinetics as the TAXUS Express Stent, it features thinner struts and a uniform architecture specifically designed for drug delivery.

One-year results from the TAXUS ATLAS SV and LL studies were published in the December 2008 issue of the Journal of American College of Cardiology. The studies both met their primary endpoint of non-inferior, nine-month, in-segment diameter stenosis versus the TAXUS Express Stent control group. They reported a significant reduction in small
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
2. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
3. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
4. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
5. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
6. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
7. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008
8. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
9. Headache Specialists Convene in Boston For 50th Annual American Headache Society Meeting
10. Leading Immunologists Convene in Boston
11. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), Industry ... (Tray-style, Manifold, & Rotary) & Geography - Global ... defines and segments the lyophilization market on the ... analyses and projections of the market size of ...
(Date:9/19/2014)... 2014  Lpath, Inc. (NASDAQ: LPTN ... announced today that it has entered into definitive ... stock and 3,605,042 unregistered warrants in a registered ... registered share of common stock and one unregistered ... stock will be $3.475.  The warrants have an ...
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
... 28 PRA International, a leading Clinical Research Organization, ... Association for the Study of Liver Diseases, The Liver ... in Boston, Massachusetts, USA. Representatives from PRA,s ... available at booth 300 to discuss our expertise in ...
... Inc. is pleased to introduce the GlideScope® Direct ... direct laryngoscopy. (Logo: http://photos.prnewswire.com/prnh/20061011/SFW044LOGO ... Made of stainless steel, the GlideScope Direct ... feel of a standard 3.5 size Macintosh blade. ...
Cached Medicine Technology:PRA International to Exhibit at Liver Diseases Conference 2Verathon® Introduces the GlideScope® Direct Intubation Trainer 2Verathon® Introduces the GlideScope® Direct Intubation Trainer 3
(Date:9/21/2014)... September 22, 2014 The asthma ... decade, as it has become saturated with relatively ... inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists ... facing increasing generic competition. However, the launch of ... and ICS/LABA therapies delivered by the next-generation inhalers ...
(Date:9/21/2014)... The Electronic Medical Records Systems ... medical records (EMR) and electronic health records (EHR) ... during the past five years and is expected ... years to 2019. The 2009 Health Information Technology ... and Medicaid incentives to encourage the widespread adoption ...
(Date:9/21/2014)... September 21, 2014 Market ... (CAS 49562-28-9) Industry, 2009-2019 is a professional ... Chinese Fenofibrate (CAS 49562-28-9) industry. The report ... (CAS 49562-28-9) including its classification, application and ... China’s top manufacturers of Fenofibrate (CAS 49562-28-9) ...
(Date:9/21/2014)... 2014 “Cluster headaches are sometimes called ... difficult to resolve,” said Steve Young of Ew Publishing; ... a pain that is more intense.” , “It should ... headaches, or migraines, that medical research is pointing to ... he added. , Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous ...
(Date:9/21/2014)... According to latest National Vital Statistics ... since 1966 (10.5 births per 1,000 women in 2013). Since ... risen steadily by 2 percent per year. The birth rate ... 50 and over) also rose, the first such increase since ... nine times as many first births to women aged 35 ...
Breaking Medicine News(10 mins):Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4
... News) -- The incidence of head and neck cancers related ... States, with the greatest increase among middle-aged white men, a ... risk factors for head and neck cancers, but the sexually ... well, according to researchers from the Louisiana State University Health ...
... Long-term follow-up of a phase II clinical trial ... non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic ... Annual Meeting 2012, held March 31 - April 4. ... to show unusually long survival in some patients," said ...
... Awakening from anesthesia is often associated with an ... restoration of awareness and orientation to one,s surroundings. ... consciousness emerges first. Using brain imaging techniques in ... Adjunct Professor Harry Scheinin, M.D. from the University ...
... (Boston) - Anurag Singh, PhD, assistant professor in ... Boston University School of Medicine has been invited ... for colon cancer at the American Association of ... Singh,s seminar, scheduled for Tuesday April 3rd, will ...
... , TUESDAY, April 3 (HealthDay News) -- Weight ... girls, self-esteem, according to a new study. "We found ... of obesity continued to see themselves as fat, despite changes ... associate professor of sociology at Purdue University in West Lafayette, ...
... Removing a lipoprotein receptor known as SR-BI may help ... presented at the American Association for Cancer Research Annual ... In vitro and mouse studies revealed that depletion of ... cell growth. SR-BI is a receptor for high-density ...
Cached Medicine News:Health News:HPV-Related Head, Neck Cancers on the Rise 2Health News:Scientists solving the mystery of human consciousness 2Health News:Scientists solving the mystery of human consciousness 3Health News:For Many Girls, Slimming Down Doesn't Help Self-Esteem 2Health News:Eliminating the 'good cholesterol' receptor may fight breast cancer 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: